Caboxen (Cabozantinib INN) 20 mg

£0.00

Cabozantinib, known by its International Nonproprietary Name (INN), is a potent oncology inhibitor used to treat various advanced cancers. Its mechanism involves targeting multiple receptor tyrosine kinases crucial for tumor growth and angiogenesis, including MET, VEGFR2, and RET. Cabozantinib is approved for metastatic medullary thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma post-sorafenib therapy. Administered orally, the dosage varies depending on cancer type and patient-specific factors. Patients require close monitoring for adverse effects like hypertension, diarrhea, fatigue, and hand-foot syndrome, with potential dosage adjustments for effective management. Cabozantinib offers promise as a significant therapeutic option for patients with resistant advanced cancers.

Add to wishlist
Share

    Indication: Cabozantinib is prescribed for treating various cancer types, including renal cell carcinoma (both advanced and hepatocellular carcinoma) and medullary thyroid cancer in patients with locally advanced or metastatic disease.

    Pharmacology: Cabozantinib functions as a tyrosine kinase inhibitor, targeting multiple receptors involved in tumor growth and angiogenesis, such as MET, VEGFRs, and RET. Its action inhibits tumor growth, angiogenesis, and affects the tumor microenvironment.

    Dosage and Administration: The recommended dosage of cabozantinib depends on the cancer type being treated. Typically, for renal cell carcinoma, the initial dose is 60 mg orally once daily, with potential adjustments based on individual patient factors and tolerability.

    Interactions: Cabozantinib may interact with various medications, including strong CYP3A4 inhibitors and inducers. Patients should inform their healthcare providers about all medications to prevent potential interactions.

    Side Effects: Common side effects of cabozantinib include fatigue, diarrhea, decreased appetite, nausea, hypertension, hand-foot syndrome, and weight loss. Serious side effects may include perforations, fistulas, hemorrhage, thromboembolism, hepatotoxicity, and osteonecrosis of the jaw.

    Precautions and Warnings: Patients on cabozantinib should be monitored for signs of hypertension, proteinuria, hemorrhage, and perforations or fistulas. Regular liver function tests are advised, and patients should avoid activities that may increase bleeding risk.

    Overdose Effects: In the event of overdose, supportive measures are recommended. No specific antidote exists for cabozantinib overdose, and treatment should focus on symptomatic and supportive care.

    Product Name

    Caboxen

    Generic Name

    Cabozantinib INN

    Formulation

    Capsule

    Available Pack size

    90 Capsules

    Strengths

    20 mg

    Reviews

    There are no reviews yet.

    Be the first to review “Caboxen (Cabozantinib INN) 20 mg”